Azam M - Search Results

1

A screen to identify drug resistant variants to target-directed anti-cancer agents.

Azam M, Raz T, Nardi V, Opitz SL, Daley GQ. Azam M, et al. Biol Proced Online. 2003;5:204-210. doi: 10.1251/bpo63. Epub 2003 Oct 24. Biol Proced Online. 2003. PMID: 14615817 Free PMC article.

2

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

Azam M, Latek RR, Daley GQ. Azam M, et al. Cell. 2003 Mar 21;112(6):831-43. doi: 10.1016/s0092-8674(03)00190-9. Cell. 2003. PMID: 12654249 Free article.

3

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ. Nardi V, et al. Among authors: azam m. Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006. Curr Opin Hematol. 2004. PMID: 14676625 Review.

4

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Weisberg E, et al. Among authors: azam m. Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007. Cancer Cell. 2005. PMID: 15710326 Free article.

5

Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.

Azam M, Daley GQ. Azam M, et al. Mol Diagn Ther. 2006;10(2):67-76. doi: 10.1007/BF03256446. Mol Diagn Ther. 2006. PMID: 16669605 Review.

6

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Azam M, et al. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. doi: 10.1073/pnas.0600001103. Epub 2006 Jun 5. Proc Natl Acad Sci U S A. 2006. PMID: 16754879 Free PMC article.

7

Farnesyl transferase inhibitor resistance probed by target mutagenesis.

Raz T, Nardi V, Azam M, Cortes J, Daley GQ. Raz T, et al. Among authors: azam m. Blood. 2007 Sep 15;110(6):2102-9. doi: 10.1182/blood-2006-12-064907. Epub 2007 May 29. Blood. 2007. PMID: 17536018 Free PMC article.

8

Activation of tyrosine kinases by mutation of the gatekeeper threonine.

Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Azam M, et al. Nat Struct Mol Biol. 2008 Oct;15(10):1109-18. doi: 10.1038/nsmb.1486. Epub 2008 Sep 14. Nat Struct Mol Biol. 2008. PMID: 18794843 Free PMC article.

9

ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Nardi V, Naveiras O, Azam M, Daley GQ. Nardi V, et al. Among authors: azam m. Blood. 2009 Apr 16;113(16):3813-20. doi: 10.1182/blood-2008-07-167189. Epub 2009 Jan 26. Blood. 2009. PMID: 19171873 Free PMC article.

10

Lin28 promotes transformation and is associated with advanced human malignancies.

Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Viswanathan SR, et al. Among authors: azam m. Nat Genet. 2009 Jul;41(7):843-8. doi: 10.1038/ng.392. Epub 2009 May 31. Nat Genet. 2009. PMID: 19483683 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

948 results

Search Page

Filters